{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:42:01Z","timestamp":1793090521099,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004770","name":"University of Parma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105238","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:06:50Z","timestamp":1772294810000},"page":"105238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"221","author":[{"given":"Sebastiano","family":"Buti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Dalla Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Acunzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Tuttobene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prisca","family":"Tamarozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Agnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Maffezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Corradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105238_bib1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5152\/tud.2022.22006","article-title":"Hypercalcemia in urological malignancies: a review","volume":"48","author":"Aggarwal","year":"2022","journal-title":"Turk. J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib2","article-title":"Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment","volume":"39","author":"Bahadoram","year":"2022","journal-title":"G Ital. Nefrol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2025.01.014","article-title":"Updated European association of urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma","volume":"87","author":"Bedke","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf426","article-title":"Immunotherapy rechallenge in metastatic renal cell carcinoma: a meta-analysis of randomized clinical trials","volume":"31","author":"Bolek","year":"2026","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105238_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102667","article-title":"Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: a systematic review and meta-analysis","volume":"122","author":"Bolek","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105238_bib6","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105238_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of Renal Cell Carcinoma: 2022 Update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/CAD.0b013e3283609ec1","article-title":"Chemotherapy in metastatic renal cell carcinoma today? A systematic review","volume":"24","author":"Buti","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2026.105238_bib9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clgc.2024.01.006","article-title":"Impact of metastatic site in favorable-risk renal cell carcinoma receiving sunitinib or pazopanib","volume":"22","author":"Catalano","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105238_bib10","article-title":"Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial","volume":"6","author":"Choueiri","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105238_bib11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105238_bib12","article-title":"Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial","volume":"43","author":"Choueiri","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105238_bib14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","article-title":"Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study","volume":"26","author":"Choueiri","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2026.105238_bib16","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2217\/fon-2023-0283","article-title":"LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma","volume":"19","author":"Choueiri","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102295","article-title":"Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis","volume":"100","author":"Ciccarese","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105238_bib18","doi-asserted-by":"crossref","DOI":"10.20517\/cdr.2025.157","article-title":"Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall?","author":"Dong","year":"2025","journal-title":"Cancer Drug Resist 854"},{"key":"10.1016\/j.critrevonc.2026.105238_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2024.07.016","article-title":"First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study","volume":"86","author":"El Zarif","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib21","unstructured":"Italian Association of Medical Oncology. AIOM Guidelines: Kidney Tumors. 2024 Edition. Milan: AIOM; 2024. Available from: https:\/\/www.aiom.it\/linee-guida-aiom-2024-tumori-del-rene\/."},{"key":"10.1016\/j.critrevonc.2026.105238_bib22","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1028::AID-CNCR19>3.0.CO;2-G","article-title":"Parathyroid hormone-related protein is an independent prognostic factor for renal cell carcinoma","volume":"86","author":"Iwamura","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105238_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eururo.2023.05.030","article-title":"A U.S. Food and drug administration-pooled analysis of frontline combination treatment survival benefits by risk groups in metastatic renal cell carcinoma","volume":"84","author":"Lee","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib24","doi-asserted-by":"crossref","first-page":"24380","DOI":"10.18632\/oncotarget.15456","article-title":"Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value of for hepatocellular carcinoma patients","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105238_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102267","article-title":"Prognostic impact of IMDC category shift from baseline to nivolumab initiation in metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 15 study","volume":"23","author":"Maiorano","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105238_bib26","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.euo.2024.03.011","article-title":"Papillary renal cell carcinoma: outcomes for patients receiving first-line immune-based combinations or tyrosine kinase inhibitors from the ARON-1 Study","volume":"7","author":"Massari","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib27","first-page":"33","article-title":"Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial","volume":"37(1)","author":"Motzer","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105238_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105238_bib30","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"CLEAR Trial Investigators. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study","volume":"42","author":"Motzer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib31","doi-asserted-by":"crossref","unstructured":"Pal, S.K., Tangen, C., Thompson, I.M. Jr., Balzer-Haas, N., George, D.J., Heng, D.Y.C., Such, B., Stein, M., Tretiakova, M., Humphrey, P., Adeniran, A., Narayan, V., Bjarnason, G.A., Vaishampayan, U., Alva, A., Zhang, T., Cole, S., Plets, M., Wright, J., Lara, P.N. Jr., 2021. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet 397, 695-703. https:\/\/doi.org\/10.1016\/S0140-6736(21)00152-5.","DOI":"10.1016\/S0140-6736(21)00152-5"},{"key":"10.1016\/j.critrevonc.2026.105238_bib32","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3389\/fimmu.2019.01805","article-title":"Platelets, thrombo-inflammation, and cancer: collaborating with the enemy","volume":"10","author":"Palacios-Acedo","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188759","article-title":"Predicting cancer evolution for patient benefit: Renal cell carcinoma paradigm","volume":"1877","author":"Pallikonda","year":"2022","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105238_bib34","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/jamaoncol.2025.1891","article-title":"First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"11","author":"Petrelli","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib35","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib36","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005445","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105238_bib38","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2026.105238_bib39","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2026.105238_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4501","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426","volume":"41","author":"Rini","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00262-024-03897-x","article-title":"First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study","volume":"74","author":"Roviello","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105238_bib42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11523-020-00707-z","article-title":"Blood myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in metastatic urothelial carcinoma","volume":"15","author":"Sheng","year":"2020","journal-title":"Target Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/OP.22.00660","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline Q&A","volume":"19","author":"Singer","year":"2023","journal-title":"JCO Oncol. Pr."},{"key":"10.1016\/j.critrevonc.2026.105238_bib44","doi-asserted-by":"crossref","first-page":"604.e9","DOI":"10.1016\/j.urolonc.2020.02.029","article-title":"Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database","volume":"38","author":"Singla","year":"2020","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134564","article-title":"Pancreatic tropism of metastatic renal cell carcinoma","author":"Singla","year":"2020","journal-title":"JCI Insight 9"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105238_bib46","article-title":"Outcomes of patients with metastatic non-clear cell renal cell carcinoma receiving contemporary or traditional first-line therapies: results from the international metastatic renal cell carcinoma database consortium","volume":"S2588-9311","author":"Takemura","year":"2026","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105238_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/17562872231187216","article-title":"The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study","volume":"15","author":"Tommasi","year":"2023","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.critrevonc.2026.105238_bib49","first-page":"733","article-title":"Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation","author":"Walther","year":"1997","journal-title":"J. Urol. 158"},{"issue":"Number 16_","key":"10.1016\/j.critrevonc.2026.105238_bib50","article-title":"Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC)","volume":"42","author":"Zarba","year":"2024","journal-title":"J. Clin. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.critrevonc.2026.105632","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000}},{"DOI":"10.1016\/j.critrevonc.2026.105632","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:45:34Z","timestamp":1775907934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"alternative-id":["S1040842826001253"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105238","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105238"}}